The World Health Organization is recommending a single dose of the typhoid conjugate vaccine for use in infants and children older than 6 months and a catch-up vaccine in children up to 15 years in countries where the infection is endemic.
The U.S. Food and Drug Administration approved Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), the first biosimilar drug to treat cancer.
GlaxoSmithKline's Nucala (mepolizumab) has been approved by the U.S. Food and Drug Administration to treateosinophilic granulomatosis with polyangiitis (EGPA).
The Centers for Medicare and Medicaid Services (CMS) is providing new policy guidance to help states design demonstration projects that promote the objectives of the Medicaid program and are consistent with federal statutory requirements.
An Internet panel survey of healthcare personnel (HCP) showed the overall influenza vaccination coverage estimate among HCP was 78.6 percent in the 2016-17 season, an increase of 15 percentage points since the 2010-11 season, but similar to the 2013-14 through 2015-16 seasons, with the highest coverage among those whose workplace had vaccination requirements.
Japanese drug maker Shionogi has created an experimental compound delivered via a single-dose pill that has been shown to effectively kill the influenza (flu) virus in patients within a single day.
The U.S. Department of Health and Human Services (HHS) has formed a new Conscience and Religious Freedom Division in the HHS Office for Civil Rights (OCR) to restore federal enforcement of U.S. laws that protect the fundamental and unalienable rights of conscience and religious freedom.
Grifols’ HyperRAB (rabies immune globulin [human]) has been approved by the U.S. Food and Drug Administration to treat rabies postexposure prophylaxis.
Plasma exchange with 5% albumin replacement was associated with marked stabilization of brain perfusion in patients with mild to moderate Alzheimer’s disease during a 21-week treatment period and reduced perfusion loss compared to control subjects at six-month follow up, according to findings from a sham-controlled Phase II clinical trial.
A recent study found that more than one-third of people with traditional Medicare spent at least 20 percent of their total income on out-of-pocket healthcare costs in 2013, and it is projected that number will increase to 42 percent by 2030.
Mylan’s Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as a biosimilar to Genentech’s Herceptin (trastuzumab).
Researchers at the University of Oxford have begun a two-year clinical trial to test a universal influenza (flu) vaccine in more than 2,000 patients.
